Everest Medicines Limited’s Definitive Agreements With Providence Therapeutics Holdings Inc.

Gowling WLG advised Providence Therapeutics Holdings Inc. on the deal.

Everest Medicines Limited announced two separate definitive agreements with Providence Therapeutics Holdings Inc., a clinical stage biotechnology company developing messenger RNA (“mRNA”) therapeutics and vaccines.

Under the terms of the agreement, Everest and Providence have agreed to license rights to Providence’s mRNA COVID-19 vaccine candidates in Asia emerging markets (including Greater China, Southeast Asia and Pakistan) and establish a broad, strategic partnership to develop mRNA products globally leveraging Providence’s cutting-edge mRNA technology platform.

The agreements further stipulate that Everest will gain rights to Providence’s mRNA COVID-19 vaccines in Greater China, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Pakistan, Philippines, Singapore, Thailand, Timor-Leste and Vietnam (“Everest Territories”). Everest will also gain rights to Providence’s next generation mRNA COVID-19 vaccine candidates against specific VOC, which are in pre-clinical development. 

A team led by Anita Nador (Picture) and Greg Peterson and advised Providence on the negotiation of these agreements. Gowling WLG’s team also included Jason Mullins and Peter Zhang (corporate) and Jasleen Chahal (life sciences/intellectual property).

Involved fees earner: Jasleen Chahal – Gowling WLG; Jason Mullins – Gowling WLG; Anita Nador – Gowling WLG; Greg Peterson – Gowling WLG; Peter Zhang – Gowling WLG;

Law Firms: Gowling WLG;

Clients: Providence Therapeutics Holdings Inc.;

Martina Bellini

Author: Martina Bellini